AI Terminal
INTERNATIONAL BIOTECHNOLOGY TST PLC
Director's Dealing • Nov 7, 2023
5163_dirs_2023-11-07_004960c1-90b4-4b66-8f43-b446039d7e11.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 6874S
Intl. Biotechnology Trust PLC
07 November 2023
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
(the "Company")
The Company was notified on 7 November 2023 that Caroline Gulliver, Non-executive Director of the Company, purchased 2,500 Ordinary 25 pence shares in the capital of the Company at a price of 573.1516 pence per Ordinary share. As a result of this purchase, Caroline Gulliver's aggregate holding of shares in the Company is 12,000 Ordinary shares, representing 0.03% of the Company's issued share capital.
Notification of dealing form
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Caroline Gulliver | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-executive Director of the Company | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | International Biotechnology Trust plc | |
| b) | LEI | 213800N1QUJ744P76D11 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares | |
| Identification code | GB0004559349 | ||
| b) | Nature of the transaction | Share purchase | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 573.1516p | 2,500 | ||
| d) | Aggregated information | Aggregated price | Aggregated volume |
| N/A | N/A | ||
| e) | Date of the transaction | 07 November 2023 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBLBDBXGGDGXR